Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Foundation Medicine Gets $111.5M Genomic Profiling Contract From VA Department

Foundation Medicine Gets $111.5M Genomic Profiling Contract From VA Department

Feb 05, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Foundation Medicine said today that it has won a nationwide contract from the US Department of Veterans Affairs National Precision Oncology Program to provide comprehensive genomic profiling for eligible veterans with advanced cancer.

The estimated contract award is $111.5 million over an anticipated period of five years, according to the Cambridge, Massachusetts-based company.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Molecular Diagnostics

  1. Patient Education Project Identifies Need for Consistent Terms in Cancer Testing

    Premium

  2. Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

  3. Canadian Consortium Launches C$2.6M Liquid Biopsy Initiative to Improve Targeted Cancer Treatment

  4. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.